Can You Ask If Someone’s Taking a GLP-1?Can You Ask If Someone’s Taking a GLP-1?
Here’s what not to say—and how not to say it. Here’s what not to say—and how not to say it.
VA Makes It Harder for Male Veterans With Breast Cancer to Get CoverageVA Makes It Harder for Male Veterans With Breast Cancer to Get Coverage
(MedPage Today) — The Trump administration is making it more difficult for veterans with a rare but deadly cancer to get their healthcare needs covered by the government. The new policy, involving breast cancer in men, is laid out in a Department…
Radiation therapy for patients with breast cancerRadiation therapy for patients with breast cancer
Radiation therapy is a common component of breast cancer treatment for patients. The high-powered beams of intense energy kill cancer cells and reduce the risk of the cancer recurring.
What do Rollerblades and Ozempic have in common?What do Rollerblades and Ozempic have in common?
If you ask a random person on the street what they call weight loss drugs, odds are, they are going to say Ozempic. It is one of the most well-known brands in medicine right now. But there’s just one problem — Ozempic is approved for type 2 diabetes, not obesity. Novo Nordisk, Ozempic’s manufacturer, does Read More
Liraglutide and Weight Loss Among Suboptimal Metabolic Bariatric Surgery RespondersLiraglutide and Weight Loss Among Suboptimal Metabolic Bariatric Surgery Responders
This randomized clinical trial examines the effect of liraglutide on weight loss, health outcomes, and adverse effects in people who had achieved a stable, suboptimal weight loss after adjustable gastric band surgery or who had regained more than 5% of their total body weight. This randomized clinical trial examines the effect of liraglutide on weight Read More
Dual GIP/GLP-1 Drug Linked to Fewer Deaths in Real-World Liver Disease StudyDual GIP/GLP-1 Drug Linked to Fewer Deaths in Real-World Liver Disease Study
(MedPage Today) — PHOENIX — Use of tirzepatide (Mounjaro, Zepbound) was associated with significantly lower risks of death, hospitalization, and major cardiovascular events compared with semaglutide (Ozempic, Wegovy) in high-risk patients with… (MedPage Today) — PHOENIX — Use of tirzepatide (Mounjaro, Zepbound) was associated with significantly lower risks of death, hospitalization, and major cardiovascular Read More
Discovery of breast cancer treatment resistance mechanism could lead to new hope for someDiscovery of breast cancer treatment resistance mechanism could lead to new hope for some
Mayo Clinic researchers have discovered a key reason why certain breast cancers might not respond to an important new class of therapeutics called antibody drug conjugates (ADCs). These treatments pair an antibody that targets cancer cells with a strong chemotherapy drug. For many patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancers, ADCs such as trastuzumab deruxtecan (T-DXd) have dramatically improved outcomes.
Obesity Drops in Adults; Wegovy’s Heart Protection; Women Turn to TestosteroneObesity Drops in Adults; Wegovy’s Heart Protection; Women Turn to Testosterone
(MedPage Today) — The obesity rate for adults in the U.S. dropped to 37% in 2025 after peaking at 39.9% in 2022, but diabetes has reached an all-time high, at 13.8%, according to a Gallup survey. Over a 10-year span, GLP-1 receptor agonists weren… (MedPage Today) — The obesity rate for adults in the Read More
Journalist Robin Davis Opens Up About Her Breast Cancer JourneyJournalist Robin Davis Opens Up About Her Breast Cancer Journey
Robin Davis, an Emmy-award winning journalist and a two-time breast cancer survivor, joins TODAY to talk about her new book called “Surviving Paris: A Memoir of Healing in the City of Light.” She opens up about what it was like being diagnosed while she was living in Paris, how she was able to find support from Hoda Kotb and more.
AI tool identifies women at high risk of interval breast cancerAI tool identifies women at high risk of interval breast cancer
In a study of more than 100,000 screening mammograms, researchers demonstrated the potential of an AI tool to help identify women at higher risk of developing interval breast cancer, which is breast cancer that is diagnosed between regular screening mammograms. Results of the new study were published today in Radiology.